Chemoprevention in Barrett’s esophagus and esophageal adenocarcinoma

There has been a dramatic increase in the incidence of Barrett’s esophagus and esophageal adenocarcinoma over the past several decades with a continued rise expected in the future. Several strategies have been developed for screening and surveillance of patients with Barrett’s esophagus and endoscop...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Gastroenterology 2021, Vol.14, p.17562848211033730-17562848211033730
Main Authors: Alkhayyat, Motasem, Kumar, Prabhat, Sanaka, Krishna O., Thota, Prashanthi N.
Format: Article
Language:English
Subjects:
Cancer
Esophageal cancer
Esophagus
Gastroenterology
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There has been a dramatic increase in the incidence of Barrett’s esophagus and esophageal adenocarcinoma over the past several decades with a continued rise expected in the future. Several strategies have been developed for screening and surveillance of patients with Barrett’s esophagus and endoscopic treatment of Barrett’s associated dysplasia and early esophageal cancer; however, they have not made a substantial impact on the incidence of cancer. Herein, chemoprevention becomes an attractive idea for reducing the incidence of cancer in Barrett’s patients. Several agents appear promising in preclinical and observational studies but very few have been evaluated in randomized controlled trials. Strongest evidence to date is available for proton-pump inhibitors and Aspirin that have been evaluated in a large randomized controlled trial. Other agents such as statins, metformin, ursodeoxycholic acid, and dietary supplements have insufficient evidence for chemoprevention in Barrett’s patients.
ISSN:1756-2848
1756-283X
1756-2848
DOI:10.1177/17562848211033730